Cochlear Limited Expands Access to Osia System for Children as Young as 5
The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the inner ear (cochlea).
Global Pharma | 20/04/2024 | By Abha | 404
Dr. Reddys Laboratories Unveils DailyBloom IBS Program to Manage IBS
Dr. Reddy’s Laboratories Ltd. has introduced its condition management program DailyBloom IBS, an integrated care plan for Irritable Bowel Syndrome (IBS).
Global Pharma | 20/04/2024 | By Aishwarya | 675
BioCryst Announces Approval of ORLADEYO from Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals has announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults.
Global Pharma | 20/04/2024 | By Aishwarya | 476
ENTOD Pharma Gets CDSCO Approval for PresVu to Treat Age-Related Vision Impairment
ENTOD Pharmaceuticals has gained approval from the Central Drugs Standard Control Organisation (CDSCO) for PresVu to treat age-related vision impairment.
Global Pharma | 19/04/2024 | By Aishwarya | 984
Scopio Labs Receives FDA Clearance for Full-Field Bone Marrow Aspirate Application
This clearance establishes a new regulatory category for all-digital bone marrow aspirate analysis software, heralding a transformative era in hematologic diagnostics.
Global Pharma | 19/04/2024 | By Abha | 544
Jubilant Generics Limited's Roorkee Facility Receives VAI Classification from USFDA
This classification signifies that the facility is deemed to be in an acceptable state of compliance with current good manufacturing practices (cGMP).
Global Pharma | 19/04/2024 | By Abha | 773
CDSCO Issues Guidelines to Curb Circulation of Substandard Pharmaceuticals
Central Drugs Standard Control Organisation (CDSCO) has recently issued draft guidelines on good distribution practices to curb the introduction of spurious, adulterated and sub-standard pharmaceutical products in the market.
Global Pharma | 19/04/2024 | By Aishwarya | 1177
Biocon Signs Exclusive Licensing and Supply Deal with Biomm for Drug Commercialization
Biocon Limited has signed an exclusive licensing and supply agreement with Biomm to commercialize its vertically integrated drug product, Semaglutide (gOzempic).
Global Pharma | 19/04/2024 | By Aishwarya | 697
Ferring Signs Commercial Gene Therapy Manufacturing Deal with SK pharmteco
Ferring Pharmaceuticals has inked an agreement with SK pharmteco to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical gene therapy Adstiladrin.
Global Pharma | 19/04/2024 | By Aishwarya | 526
OrthoIndy Introduces Augmented Reality into Surgical Procedures
OrthoIndy has announced a monumental step forward in surgical innovation by introducing augmented reality (AR) into surgical procedures.
Global Pharma | 18/04/2024 | By Manvi | 368
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy